Releases - Biotage

View:

2004

 

Found press releases

 

Allotment of employee stock options in Biotage

12/21/2004 12:03 PM EST
Contact: Jeff Bork, President and CEO Tel: +46 734 22 16 60 Uppsala, December 21, 2004. At the Annual General Meeting of shareholders held on April 22, 2002, a global employee stock option program was adopted for the employees of the group. The Board has on December 21, 2004 resolved to allot 446,000 employee stock options to 203 persons in accordance with the option program, of which members of the senior...

Biotage issues 5.7 million new shares to Catella Healthcare

12/15/2004 2:31 AM EST
Contact: Jeff Bork, President and CEO Tel: +46 734-22 16 60 Mikael Widell, Head of Communications, Catella Holding AB Tel: +46 703-11 99 60   Uppsala December 15, 2004. On 14 December 2004, the board of Biotage AB resolved to increase the company’s share capital by means of a new issue of 5.7 million shares to Catella Healthcare AB. The resolution was based on the...

Biotage Interim report January - September 2004

10/21/2004 7:29 AM EST
·Sales in the period January - September 2004 amounted to 260.4 MSEK
(68.6 MSEK and 250.0 MSEK pro-forma), corresponding to a pro-forma increase by 4
percent
·Sales in the third quarter were negatively affected by delays in the deliveries of the new
purification system and amounted to 84.5 MSEK
·During the period restructurings were made which added 5 MSEK to the operating costs
but...

No sales increase in the third quarter due to delayed deliveries

10/5/2004 9:32 AM EST
Contact:
Jeff Bork, President and CEO
Tel: +46 734 22 16 60

Uppsala 5 October 2004
Deliveries of the new system for purification of drug compounds, SPX, that Biotage launched in the summer have been delayed three months. Therefore, estimated sales for the third quarter is between 83 and 85 MSEK.

The delay of the SPX systems depends on software development delays....

Biotage expands licence agreement with 454 Corporation

9/17/2004 4:25 AM EST
Contact:
Jeff Bork, President and CEO
Tel: +46 734 22 16 60

Uppsala 17 September 2004
Biotage and 454 Corporation have expanded the one-year-old license agreement, which gave 454 Corporation exclusive rights to use sequencing by synthesis and pyrophosphate based sequencing for whole genome and other high density and high throughput applications. The expanded license gives 454...

New large orders for Biotage

8/31/2004 8:17 AM EST
Contact:
Jeff Bork, President and CEO
Tel: +46 734 22 16 60
Dave Patteson, President Discovery Chemistry
Tel: +1 434 979 2319

31 August, 2004
Biotage's newly launched systems for synthesis and purification of drug compounds have received an immediate response in the market. One of the largest pharmaceutical companies in the world has ordered instruments...

Interim report January-June 2004

8/12/2004 9:55 AM EST
Contacts:
Jeff Bork, President & CEO
Tel: +46 734-22 16 60
Mats-Olof Wallin, CFO
Tel: +46 705-93 52 73


·Second quarter sales were up by 27% over the previous year's pro forma figure and order bookings exceeded 100 MSEK
·Sales for the first six months improved to MSEK 175.9 (41.2 and 158.4 pro forma)
·Operating expenses during the quarter...

Extraordinary general meeting in Biotage - Authorization to the Board

7/20/2004 6:15 AM EST
Uppsala 20 July, 2004
The Extraordinary General Meeting of Biotage has today resolved to authorize the Board of Directors to issue new shares not exceeding in total 5,700,000 new shares, with or without deviation from the shareholders' pre-emption rights, to be paid for in cash, through an issue in kind or through set-off. Issues may be made in order to finance company acquisitions or to strengthen the...

NOTICE OF EXTRAORDINARY GENERAL MEETING OF BIOTAGE AB

6/30/2004 12:00 PM EST
Press release Biotage AB
Kungsgatan 76
Contact: SE-753 18 Uppsala
Jeff Bork, President and CEO Tel+46 18 56 59 00
Tel: +46 734 22 16 60 www.biotage.com





Uppsala 30 June, 2004




Shareholders in Biotage AB, Reg. No. 556539-3138, are hereby invited to attend the Extraordinary General Meeting, to be held...

Extraordinary general meeting in Biotage

6/29/2004 2:00 AM EST
Press release Biotage AB
Kungsgatan 76
Contact: SE-753 18 Uppsala
Jeff Bork, President and CEO Tel+46 18 56 59 00
Tel: +46 734 22 16 60 www.biotage.com




Uppsala 28 June, 2004




The Board of Directors of Biotage has resolved to convene an extraordinary general meeting in order to adopt a resolution to...

Biotage

Biotage accelerates the drug discovery and development process and increases the knowledge of the importance of the genetic make-up by providing complete solutions for medicinal chemistry research and applied genetic ana...

View more


  CONTACT